[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nausea-and-vomiting\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nausea-and-vomiting":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,61,86,122,151,178,206,236,257],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":60},"100573018","phase-4-broadening-antiemetics-research-by-comparing-the-effectiveness-of-fosaprepitant-and-metoclopramide-100573018",false,"NCT06740812","Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide","Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide: A Randomized Control Trial","BARF RCT","Inclusion Criteria:\n\n* Adults at least 18 years old\n* Present to ED for treatment of Nausea and\u002For vomiting as defined by the International Classification of Diseases (ICD-10) or identified by treating clinician\n\nExclusion Criteria:\n\n* Pregnancy, desiring pregnancy, or lactating\n* Antiemetic use or intravenous fluids prior to presenting to ED for evaluation and management\n* Bradycardia (\\\u003C 60 bpm heart rate)\n* Prolonged QTc (greater than 490ms)\n* Not conversant in English or Spanish\n* Altered mental status\n* Dementia\n* Lack of phone for follow-up communication","ALL","18 Years",{"count":20,"type":21},212,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The study team proposes a double-blind, comparative effectiveness, randomized controlled trial (RCT) to address the following goal: to determine the relative efficacy and adverse event profile of fosaprepitant compared to the standard of care antiemetic metoclopramide. Fosaprepitant and its active metabolite aprepitant are a relatively new class of antiemetic that exclusively acts in the central nervous system by blocking neurokinin (NK-1) which is a key signaling molecule in the centrally mediated aspects of the vomiting reflex. Currently, fosaprepitant and aprepitant both have only two United Stated Food and Drug Administration (USFDA) approved indications for nausea and vomiting: chemotherapy-induced and postoperative. Neurokinin inhibitors are highly effective and generally well-tolerated. Therefore, this class of medication may be a more appropriate medication for the millions of patients with nausea and vomiting that seek care in emergency departments (EDs). Intravenous fosaprepitant is converted to the active metabolite aprepitant on the order of minutes and is significantly cheaper to procure at this time.",[27,28,29],"Nausea and Vomiting","Nausea","Vomiting",[31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47],"Signs and Symptoms, Digestive","Antiemetics","Autonomic Agents","Peripheral Nervous System Agents","Physiological Effects of Drugs","Gastrointestinal Agents","Antipruritics","Dermatologic Agents","Neurotransmitter Agents","Molecular Mechanisms of Pharmacological Action","Neurokinin-1 Receptor Antagonists","Fosaprepitant","Aprepitant","Dopamine Receptor Antagonist","Randomized Control Trial","Metoclopramide","Adults","NOT_YET_RECRUITING","2026-06-25",{"date":51,"type":52},"2026-06-29","ACTUAL",{"date":54,"type":21},"2026-12",{"date":56,"type":21},"2027-09",{"name":58,"class":59},"Montefiore Medical Center","OTHER",1,{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":68,"targetDuration":4,"studyType":22,"phases":70,"briefSummary":73,"conditions":74,"keywords":75,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":60},"100545446","phase-2-antiemetic-fosaprepitant-to-remedy-nausea-and-vomiting-100545446","NCT06382012","Antiemetic Fosaprepitant To Remedy Nausea and Vomiting","AFTR NV RCT","Inclusion Criteria:\n\n* Adults at least 18 years old\n* Present to an emergency department (ED) for nausea and\u002For vomiting as defined by the International Classification of Diseases (ICD-10), or identified by treating clinician\n* Following the approval of a protocol amendment, study patients who have received an antiemetic and remain persistently nauseated after 2 hours will be eligible to participate in the study\n\nExclusion Criteria:\n\n* Pregnancy, desiring pregnancy, or lactating\n* Antiemetic medication use less than 2 hours prior to screening\n* Bradycardia (heart rate less than 60 bpm heart rate)\n* Prolonged QTc (\\>480ms)\n* Not conversant in English or Spanish\n* Altered mental status\n* Dementia\n* Lack of phone for follow-up communication",{"count":69,"type":21},200,[71,72],"PHASE2","PHASE3","The study team proposes a randomized, double-blind, RCT to address the following goal: to determine the relative efficacy and adverse event profile of fosaprepitant compared to the standard of care antiemetic ondansetron. Fosaprepitant and its active metabolite aprepitant are a relatively new class of antiemetic that exclusively acts in the central nervous system by blocking neurokinin (NK-1) which is a key signaling molecule in the centrally mediated aspects of the vomiting reflex. Currently, fosaprepitant and aprepitant both have only two United Stated Food and Drug Administration (USFDA) approved indications for nausea and vomiting: chemotherapy-induced and postoperative. Neurokinin inhibitors are highly effective and generally well-tolerated. Therefore, this class of medication may be a more appropriate medication for the millions of patients with nausea and vomiting that seek care in EDs. Intravenous fosaprepitant is converted to the active metabolite aprepitant on the order of minutes and is significantly cheaper to procure at this time. The outcome for the efficacy analysis will be no need for additional medication to treat nausea and vomiting within 2 hours of investigational medication administration. The primary outcome for the tolerability analysis will be the development of any new symptom within 2 hours of medication administration.",[27,28,29],[42,29,45,76,47],"Ondansetron","RECRUITING","2026-05-14",{"date":80,"type":52},"2026-05-18",{"date":82,"type":52},"2024-11-13",{"date":84,"type":21},"2027-03",{"name":58,"class":59},{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":22,"phases":95,"briefSummary":97,"conditions":98,"keywords":108,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":60},"100635703","dexmedetomidine-and-propofol-for-sedation-in-cataract-surgery-100635703","NCT07556133","Dexmedetomidine and Propofol for Sedation in Cataract Surgery.","Dexmedetomidine vs Propofol for Sedation in Cataract Surgery : a Prospective Randomized Controlled Trial.","Inclusion Criteria:\n\n* Adults undergoing cataract surgery\n\nExclusion Criteria:\n\n* Severe hepatic insufficiency\n* Third degree AV block\n* Patient refusal",{"count":94,"type":21},1000,[96],"NA","The goal of this prospective, randomized, single-blinded is to learn if there is an ideal sedation protocol in cataract surgery in adults.\n\nThe main questions it aims to answer are:\n\n* Does the combination of Dexmedetomidine and Propofol affect significantly Ramsay sedation scale, compared to Dexmedetomidine and compared to Propofol?\n* How does each sedation protocol affect hemodynamics? (Heart rate and blood pressure)\n* Are respiratory events more common in a certain group?\n* Is the surgeon's satisfaction similar among groups?\n* Are adverse effects (bradycardia, hypotension, nausea) more common in a certain group?\n\nResearchers will compare 3 sedation protocols : Dexmedetomidine versus Propofol versus the combination of these 2 drugs and to see if one protocol is overall superior to the others. Fentanyl will also be used in all 3 sedation protocols.\n\nParticipants will :\n\n* Receive one of these three protocols\n* Be operated for one or both eyes\n* Monitored during the whole surgery and in the recovery room\n* Be evaluated by the Ramsay sedation scale by a trained Anesthesiologist or CRNA during surgery and in the recovery room Surgeons will be asked about how much they were satisfied.",[99,100,101,102,103,104,105,106,107,27],"Sedation","Cataract","Hemodynamic","Hemodynamic Changes","Dexmedetomidine","Propofol Dosage","Fentanyl","Bradycardia","Tachycardia",[109,100,110,111,112],"Dexmedetomidine and propofol in cataract surgery","sedation","Dexmedetomidine in cataract surgery","Sedation for cataract surgery","2026-04-21",{"date":115,"type":52},"2026-04-29",{"date":117,"type":52},"2025-11-09",{"date":119,"type":21},"2026-12-09",{"name":121,"class":59},"Saint-Joseph University",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":129,"sex":17,"minAge":18,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":22,"phases":133,"briefSummary":134,"conditions":135,"keywords":137,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":150},"100627269","phase-3-a-study-to-evaluate-tradipitant-on-treating-nausea-and-vomiting-induced-by-glp-1r-agonist-use-100627269","NCT07446439","A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use","The Thetis Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Tradipitant on Nausea and Vomiting After GLP-1R Agonist Administration in Healthy Overweight or Obese Volunteers","Inclusion Criteria:\n\n* Body Mass Index ≥ 25 and \\\u003C 40 kg\u002Fm\\^2\n* No serious medical problems or chronic diseases, specifically no type I or type II diabetes\n\nExclusion Criteria:\n\n* Another disorder that contributes to gastrointestinal symptoms\n* History of intolerance and\u002For hypersensitivity to NK-1 receptor antagonists\n* History of intolerance and\u002For hypersensitivity to GLP-1 receptor agonists\n* Exposure to any investigational medication within the past 60 days",true,"65 Years",{"count":132,"type":21},280,[72],"The goal of this study is to measure the effects of using Tradipitant to treat nausea and vomiting induced by GLP-1R agonist use in adults with class I or class II obesity, or adults who are overweight with at least one weight-related condition. The study is placebo-controlled with two treatment arms.",[27,136],"Obesity",[138,139,28,29],"GLP-1R agonist","Semaglutide","2026-04-14",{"date":142,"type":52},"2026-04-20",{"date":144,"type":52},"2026-03-27",{"date":146,"type":21},"2026-12-01",{"name":148,"class":149},"Vanda Pharmaceuticals","INDUSTRY",10,{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":17,"minAge":158,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":160,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":60},"100185996","phase-3-domperidone-in-treating-patients-with-gastrointestinal-disorders-100185996","NCT01696734","Domperidone in Treating Patients With Gastrointestinal Disorders","Treatment Protocol for the Compassionate Use of Domperidone","Inclusion Criteria:\n\n* Patients with GI disorders who have failed standard therapy\n* Symptoms or manifestations of: a) gastroparesis; b) refractory gastroesophageal reflux disease (GERD) including persistent esophagitis, refractory heartburn, reflux-related laryngitis, and respiratory symptoms; or c) severe dyspepsia\n* Completion of a comprehensive evaluation, including clinical history and physical examination, to eliminate other causes of their symptoms\n* Patient has signed the informed consent document agreeing to the use of the study drug, domperidone\n* White blood cell (WBC) with differential greater than 3,000\u002Fml\n* Alkaline phosphatase less than 1.5 x upper limit of normal\n* Alanine aminotransferase (ALT) less than 2 x upper limit of normal\n* Aspartate aminotransferase (AST) less than 2 x upper limit of normal\n* Bilirubin less than or equal to 2 x upper limit of normal\n* Blood urea nitrogen (BUN) less than 2 x upper limit of normal\n* Creatinine less than 1.5 x upper limit of normal\n* Stable hemoglobin greater than or equal to 8.0 g\u002Fdl\n* Potassium between range of 3.0 to 5.5\n* Magnesium level between 1.6-2.6 mg\n\nExclusion Criteria:\n\n* Patients with the following cardiac diagnoses: ventricular tachycardia or fibrillation; Torsade des Pointes; clinically significant bradycardia; sinus node dysfunction; heart block; prolonged QTc interval (QTc \\> 450 milliseconds for males, QTc \\> 470 milliseconds for females); prior specific cardiovascular conditions of clinically significant valvular heart disease requiring medication, ischemic, or pulmonary heart disease; cardiomyopathy; history of heart failure\n* Patients who are receiving antiarrhythmic medications with action on repolarization times (with prolongation of the QTc interval such as amiodarone, disopyramide, dofetilide, flecainide, ibutilide, quinidine, sotalol, dronedarone etc.)\n* Patients who are receiving monoamine oxidase (MAO) inhibitors\n* Patients with a history of or active liver failure\n* Clinically significant electrolyte disorders including sodium \\\u003C 130 or \\> 145 and\u002For potassium \\\u003C 3.0 or \\> 5.5 and\u002For magnesium \\\u003C 1.6 or \\> 2.6\n* GI hemorrhage or obstruction experienced within the previous 6 weeks\n* Presence of a prolactinoma (prolactin-releasing pituitary tumor)\n* Pregnant or breast-feeding female (women of childbearing potential \\[WOCBP\\], defined as not post-menopausal for 12 months or without previous surgical sterilization, must have a negative urine pregnancy test within 30 days of the first administration of domperidone and must either commit to continued abstinence from heterosexual intercourse or use an effective method of birth control during the course of the study)\n* Known allergy to domperidone","16 Years",{"count":69,"type":21},[72],"This phase III trial studies how well domperidone works in treating patients with gastrointestinal disorders. Domperidone may help control chronic gastrointestinal disorders and their symptoms, such as pain, bloating, and nausea and vomiting, by stimulating contraction of the stomach to increase its ability to empty itself of food.",[163,164,165,166,167,168,27],"Digestive System Disorder","Dyspepsia","Esophagitis","Gastroesophageal Reflux Disease","Gastroparesis","Heartburn","2026-04-10",{"date":171,"type":52},"2026-04-13",{"date":173,"type":52},"2012-10-23",{"date":175,"type":21},"2027-10-31",{"name":177,"class":59},"M.D. Anderson Cancer Center",{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":129,"sex":186,"minAge":18,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":190,"phases":4,"briefSummary":191,"conditions":192,"keywords":193,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":204,"locationsCount":60},"100547984","prevalence-of-hyperemesis-gravidarum-100547984","NCT06415084","Prevalence of Hyperemesis Gravidarum","Hyperemesis Gravidarum Prevalence : A Repeated Cross-sectional Population Based Study","PHyperEG1","Inclusion Criteria:\n\n* Women having a monitored pregnancy in Auvergne,\n* Major,\n* Speaking French,\n* Socially insured,\n* Having given their agreement to participate in the study.\n\nExclusion Criteria:\n\n* Women refusing to participate in the study,\n* Not speaking French,\n* Major incapacitated persons.","FEMALE","50 Years",{"count":189,"type":21},604,"OBSERVATIONAL","Nausea and vomiting during pregnancy represent one of the most common symptoms of pregnancy, affecting 35 to 91% of women. Most often, the symptoms are mild, without impairment of quality of life and disappear at the end of the first trimester. More severe forms constitute hyperemesis gravidarum (HG) (hyperemesis gravidarum). In approximately 35% of women, nausea and vomiting during pregnancy are disabling, alter daily life and professional activity and negatively affect family relationships. For 0.3 to 3.6% of pregnancies, this vomiting is uncontrollable and constitutes the main cause of hospitalization in the first trimester of pregnancy.\n\nFaced with the incomprehension and lack of knowledge of their illness, both in society and in the medical community, patient associations have been created in France to gain recognition for HG and raise awareness among caregivers and women about this illness and its consequences. Vomiting repeatedly for weeks, losing weight sometimes significantly, being weakened, no longer able to cope with daily life, family life and work, is what some women can experience while they are pregnant and that society tells them : \"pregnancy is not an illness\".\n\nAlthough HG is common, its real prevalence is unknown, particularly in France, because there have been few studies involving small samples. A population study is desirable because it is likely that the prevalence of these pregnancy aches differs depending on the country. This subject is important because vomiting during pregnancy has an impact on women's quality of life and their desire to become pregnant again.\n\nThe main objective of this observation study is to evaluate the prevalence of pregnancy-related nausea and\u002For vomiting (uncomplicated or with hyperemesis gravidarum), in the general population, in the first trimester of pregnancy.\n\nThe secondary objectives are:\n\n* to assess the prevalence of pregnancy-related nausea and\u002For vomiting (uncomplicated or with hyperemesis gravidarum), in the second and third trimesters of pregnancy,\n* to assess the prevalence of uncomplicated pregnancy-related nausea and\u002For vomiting in the three trimesters of pregnancy,\n* to evaluate the prevalence of hyperemesis gravidarum (with or without hospitalization) in the three trimesters of pregnancy,\n* to evaluate the prevalence of hyperemesis gravidarum requiring hospitalization in the three trimesters of pregnancy,\n* to evaluate the distribution of nausea and\u002For vomiting (mild, moderate and severe) according to the modified-PUQE score, in the three trimesters of pregnancy,\n* to evaluate the predictive factors for the occurrence of pregnancy-related nausea and\u002For vomiting (uncomplicated or with hyperemesis gravidarum) in the first trimester of pregnancy,\n* to assess health-related quality of life in the event of pregnancy-related nausea and\u002For vomiting (uncomplicated or with hyperemesis gravidarum), in the three trimesters of pregnancy,\n* and to compare health-related quality of life between women with pregnancy-related nausea and\u002For vomiting (uncomplicated or with hyperemesis gravidarum) and those without, in the first trimester of pregnancy.",[27],[194,195,196,197],"Nausea vomiting","Pregnancy","Disease prevalence","Hyperemesis gravidarum","2025-05-05",{"date":200,"type":52},"2025-05-06",{"date":202,"type":52},"2025-05-01",{"date":54,"type":21},{"name":205,"class":59},"University Hospital, Clermont-Ferrand",{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":129,"sex":17,"minAge":18,"maxAge":213,"enrollmentInfo":214,"targetDuration":4,"studyType":22,"phases":216,"briefSummary":217,"conditions":218,"keywords":221,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":60},"100531466","phase-3-electroacupuncture-for-the-prevention-of-chemotherapy-induced-nausea-and-vomiting-in-patients-with-breast-cancer-100531466","NCT06200168","Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer","A Study on Electroacupuncture Combined With Olanzapine-contained Four-drug Antiemetic Therapy for the Prevention of Highly Emetogenic Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer (ECO Study)","Inclusion Criteria:\n\n1. Aged 18 years or older and aged 75 years or younger, of any nationality;\n2. Eastern Cooperative Oncology Group performance status of 0-2;\n3. Patients with breast cancer, with no restrictions on molecular typing; early-stage patients must not have undergone prior chemotherapy, while advanced-stage patients must be candidates for first-line chemotherapy and have declined neoadjuvant or adjuvant chemotherapy for over 3 months. All patients must receive highly emetogenic chemotherapy (HEC) based on anthracycline chemotherapy with cyclophosphamide (EC or AC) or carboplatin (AUC≥4)\u002Fcisplatin;\n4. Predicted life expectancy of ≥3 months;\n5. Adequate bone marrow, kidney, and liver function;\n6. Adequate contraception if premenopausal women;\n7. Written informed consent by the patient before enrolment.\n\nExclusion Criteria:\n\n1. Patients already submitted to chemotherapy;\n2. Is scheduled to receive any non-HEC on Day 1;\n3. Is scheduled to receive any chemotherapy on days 2-4 after HEC;\n4. Received or is scheduled to receive radiation therapy to the abdomen, pelvis, head and neck within 1 week prior to Day 1 or between Days 1 to 5 in cycle 1;\n5. Has symptomatic primary or metastatic symptomatic central nervous system malignancy causing nausea and\u002For vomiting;\n6. Have ongoing emesis or CTCAE grade 2 or greater nausea;\n7. Significant medical or mental conditions;\n8. Any allergies to study drug, antiemetics or dexamethasone;\n9. Significantly abnormal laboratory values (platelets, coagulation indexes, absolute neutrophils, AST, ALT, bilirubin or creatinine);\n10. Patients who are pregnant or breast-feeding;\n11. Inflammatory skin reaction;\n12. Has lymphedema in acupuncture stimulation area;\n13. Patients who are afraid of electroacupuncture stimulation or allergic to stainless steel needles;\n14. Received acupuncture treatments for any conditions less than 4 weeks before HEC;\n15. Currently using drugs with antiemetic activity (e.g., 5-HT3 receptor antagonists, corticosteroids (except when used at physiological doses), dopamine receptor antagonists, minor tranquilizers, antihistamines, and benzodiazepines (except for nocturnal sedation));\n16. Patients with concomitant severe diseases or with a predisposition to emesis such as gastrointestinal obstruction, active peptic ulcer, and hypercalcemia and symptomatic brain metastasis;\n17. Has a convulsive disorder requiring anticonvulsant treatment;\n18. Patients administered thioridazine as a chronic antipsychotic medication (patients are allowed to receive prochlorperazine and other phenothiazines as a rescue antiemetic treatment);\n19. Concurrent treatment with quinolone antibiotics;\n20. Has a history of chronic alcoholism (determined by the investigator);\n21. Known arrhythmias, uncontrolled congestive heart failure, or acute myocardial infarction within the past six months;\n22. Has a history of uncontrolled diabetes (e.g., using insulin or oral hypoglycemic agents).","75 Years",{"count":215,"type":21},370,[72],"This randomized controlled phase III trial aims to evaluate the use of electroacupuncture in combination with olanzapine-containing standard quadruple antiemetic drugs for the treatment of nausea and vomiting induced by highly emetogenic chemotherapy (HEC) in patients with breast cancer. Furthermore, it will analyze the relationship between single nucleotide polymorphism and electroacupuncture treatment for chemotherapy-induced nausea and vomiting.",[219,220,27],"Electroacupuncture","Olanzapine-contained Four-drug Antiemetic",[222,223,224,225,226],"electroacupuncture","olanzapine-contained four-drug antiemetic","nausea and Vomiting","breast cancer","chemotherapy","2025-03-27",{"date":229,"type":52},"2025-04-02",{"date":231,"type":52},"2024-01-16",{"date":233,"type":21},"2026-12-31",{"name":235,"class":59},"Jiuda Zhao",{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":129,"sex":17,"minAge":18,"maxAge":213,"enrollmentInfo":243,"targetDuration":4,"studyType":22,"phases":244,"briefSummary":245,"conditions":246,"keywords":247,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":60},"100540289","phase-3-electroacupuncture-plus-antiemetic-therapy-for-chemotherapy-induced-nausea-and-vomiting-in-patients-with-breast-cancer-100540289","NCT06314906","Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer","Combining Electroacupuncture With Antiemetic Therapy for Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer: A Clinical Study","Inclusion Criteria:\n\n1. Patients aged 18 to 75 years, inclusive, from any nationality.\n2. Patients diagnosed with early-stage breast cancer.\n3. Eastern Cooperative Oncology Group performance status ranging from 0 to 2.\n4. All patients must undergo highly emetogenic chemotherapy (HEC).\n5. Adequate organ function.\n6. Adequate contraception required for premenopausal women.\n\nExclusion Criteria:\n\n1. Scheduled to undergo chemotherapy between days 2 to 4 following HEC.\n2. Received or is planned to receive abdominal radiation therapy within 1 week before Day 1 in cycle 1.\n3. Significant medical or psychological conditions.\n4. Presents with symptomatic primary or metastatic central nervous system malignancy causing nausea and\u002For vomiting.\n5. Experiencing ongoing vomiting or nausea of grade 2 or higher according to Common Terminology Criteria for Adverse Events (CTCAE).\n6. Any known allergies to the study drug, antiemetics, or dexamethasone.\n7. Patients who have fear of electroacupuncture stimulation or are allergic to stainless steel needles.\n8. Received acupuncture treatments for any conditions within 8 weeks prior to HEC.",{"count":215,"type":21},[72],"This study explores the effectiveness of combining electroacupuncture with olanzapine-containing four-drug antiemetic therapy to mitigate chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer. The research aims to assess the adjunctive benefits of electroacupuncture in enhancing the antiemetic effects of conventional medication, particularly in the context of highly emetogenic chemotherapy regimens. By investigating the synergistic potential of these modalities, the study seeks to provide insights into optimizing supportive care strategies for patients with breast cancer undergoing intensive chemotherapy treatment.",[219,220,27],[222,223,224,225,226],"2024-03-19",{"date":250,"type":52},"2024-03-21",{"date":252,"type":52},"2024-03-07",{"date":254,"type":21},"2027-03-31",{"name":256,"class":59},"Feixue Song",{"id":258,"slug":259,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":263,"eligibilityCriteria":264,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":213,"enrollmentInfo":265,"targetDuration":4,"studyType":22,"phases":267,"briefSummary":268,"conditions":269,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":60},"100492335","the-safety-and-effectiveness-of-palonosetron-hydrochloride-capsule-was-used-to-cinv-100492335","NCT05690802","The Safety and Effectiveness of Palonosetron Hydrochloride Capsule Was Used to CINV","Palonosetron Hydrochloride Capsules (Ruoshan ®) Used to Prevent and Control Chemotherapy for Tumor Patients Real World Study on the Safety of Nausea and Vomiting Reduction","TSEPHCC","Inclusion Criteria:\n\n* For patients with malignant tumors who can accept chemotherapy, the disease type is not limited. The specific chemotherapy scheme is the chemotherapy scheme with moderate risk of vomiting (for the risk level of vomiting, refer to the 2019 CSCO anti-tumor treatment related nausea and vomiting prevention and treatment guidelines);\n* 18-75 years old, KPS score ≥ 70, and the expected survival time is more than 3 months;\n* Before treatment, ECG, blood routine test, liver and kidney functions and electrolytes were basically normal;\n* All patients signed the informed consent form\n\nExclusion Criteria:\n\n* Patients with chemotherapy contraindications, patients allergic to 5-HT3RA, pregnant women and lactating women;\n* People with digestive tract obstruction; Patients with serious heart disease, liver and kidney disease and metabolic disorder; Patients suffering from epilepsy or using psychotropic and sedative drugs;\n* Used antiemetic drugs or chemicals within 24 hours.Those who have vomited before treatment may have brain metastasis, intracranial hypertension, gastrointestinal obstruction, psychological abnormalities, etc.Patients with factors causing nausea and vomiting.",{"count":266,"type":21},1060,[96],"To observe and evaluate the safety and effectiveness of Palonosetron hydrochloride capsule in preventing acute nausea and vomiting caused by moderate emetic chemotherapy; The characteristics of the applicable population, clinical medication and clinical benefits of Palonosetron Hydrochloride Capsules were analyzed.",[27],"2023-01-18",{"date":272,"type":52},"2023-01-19",{"date":274,"type":52},"2022-05-16",{"date":276,"type":21},"2029-05-30",{"name":278,"class":59},"Xijing Hospital"]